Skip to main content
Clinical Trials/NCT06413459
NCT06413459
Recruiting
Not Applicable

Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis

Ospedale San Raffaele1 site in 1 country40 target enrollmentApril 8, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-Tuberculous Mycobacterial Pneumonia
Sponsor
Ospedale San Raffaele
Enrollment
40
Locations
1
Primary Endpoint
profile of specific cell populations and expression markers to determine the development and progression of M. abscessus lung disease in patients with CF
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

In this project the investigators aim to identify new biological markers by characterizing the response/inflammation associated with the development and progression of M. abscessus lung disease in patients suffering from cystic fibrosis with the aim of increasing current knowledge available on the development and progression of lung disease.

Detailed Description

Main objective: Evaluate the correlation between early alterations in the profile of specific cell populations or expression markers or soluble immunity activation proteins, considering in particular the development and progression of M. abscessus lung disease in patients with cystic fibrosis. Secondary objectives * Identify cellular expression profiles associated with the development and progression of M. abscessus lung disease in cystic fibrosis patients and evaluate its ability to predict clinical outcome * Identify biomarkers or molecular profiles associated with the development and progression of M. abscessus lung disease in cystic fibrosis patients and evaluate its ability to predict clinical outcome * Expand pathogenetic knowledge to support disease progression pulmonary disease from M. abscessus in patients with cystic fibrosis and evaluate their ability to predict clinical outcome. * Describe the reciprocal interactions between cellular and humoral components of the response inflammatory disease during M. abscessus infection with/without M. abscessus lung disease.

Registry
clinicaltrials.gov
Start Date
April 8, 2021
End Date
March 30, 2027
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Ospedale San Raffaele
Responsible Party
Principal Investigator
Principal Investigator

Nicola Lore

Principal Investigator

Ospedale San Raffaele

Eligibility Criteria

Inclusion Criteria

  • Patients with a certain diagnosis of cystic fibrosis and visited during normal clinical practice, in accordance with the standard operating procedures in force at the Centres.
  • Both sexes
  • Age \>18 years
  • Obtaining informed consent for patients (based on the procedures established by the protocol).

Exclusion Criteria

  • Patients unable to understand the instructions and information provided and be able to adequately accept the study methods.

Outcomes

Primary Outcomes

profile of specific cell populations and expression markers to determine the development and progression of M. abscessus lung disease in patients with CF

Time Frame: One month after enrollment visit

Evaluate the correlation between early alterations in the profile of specific cell populations or expression markers or soluble immunity activation proteins, considering in particular the development and progression of M. abscessus lung disease in patients with cystic fibrosis

Study Sites (1)

Loading locations...

Similar Trials